Table 2.
MPPs | LD50 (mg kg−1) | Groups | Control group | 1 | 2 | 3 | 4 |
---|---|---|---|---|---|---|---|
CTP | 21.345 | Dose (mg kg−1) | 0 | 19.5 | 20 | 20.5 | 22 |
Mortality | 0/10 | 2/10 | 3/10 | 4/11 | 6/10 | ||
Mortality (%) | 0 | 20 | 30 | 36.4 | 60 | ||
TAT | 27.244 | Dose (mg kg−1) | 0 | 25 | 27 | 28 | 30 |
Mortality | 0/10 | 2/9 | 4/9 | 5/9 | 7/8 | ||
Mortality (%) | 0 | 22.2 | 44.4 | 55.6 | 87.5 | ||
R11 | 16.508 | Dose (mg kg−1) | 0 | 15.5 | 16 | 16.5 | 17 |
Mortality | 0/10 | 1/10 | 3/10 | 5/10 | 7/10 | ||
Mortality (%) | 0 | 10 | 30 | 50 | 70 | ||
TD | >140 | Dose (mg kg−1) | 0 | 80 | 100 | 140 | – |
Mortality | 0/10 | 0/2 | 0/8 | 0/8 | – | ||
Mortality (%) | 0 | 0 | 0 | 0 | – |
MPPs, membrane‐permeable peptides.